Hepatitis B Vaccine Market By Composition (Combination Vaccines, Mono Vaccines), By End Users Age (Adult Hepatitis B Vaccines, Paediatric Hepatitis B Vaccines) - Growth, Future Prospects And Competitive Analysis 2017 - 2025

Factors such as increased awareness of hepatitis B infection prevention and the fact that governments in many countries have mandated immunization and hepatitis B vaccine inclusion in the national immunization schedule are driving the global market growth for the hepatitis B vaccine.

The report titled "Hepatitis B Vaccine Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall hepatitis B vaccine market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on composition, end users' ages, and different geographical regions.

In order to help strategic decision-makers, the report also includes sections on the competitive profiling of the leading players in the global hepatitis B vaccine market, attractive investment propositions, and market positioning of key manufacturers.

Geographically, the global hepatitis B vaccine market is studied for the following regional markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hepatitis B vaccine market.

Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive scenario of the global hepatitis B vaccine market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hepatitis B vaccine market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hepatitis B vaccine market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on composition, the global hepatitis B vaccine market is segmented as follows:

  • Mono Vaccines
  • Combination Vaccines

Hepatitis B is a life-threatening liver infection caused by the hepatitis B virus. A vaccine is more effective than any other treatment at preventing infection. According to the WHO (World Health Organization), the prevalence of hepatitis B is highest in the Western Pacific and African regions, however, and lowest in the American population. Factors such as an increase in awareness of vaccines are expected to contribute to the market growth of the hepatitis B vaccine globally. For the purposes of this study, the market is divided into segments based on vaccine composition, such as monovalent and combination vaccines. Combination vaccines that protect against multiple pathogens involve the combination of multiple antigens into a single vaccine.

Combination vaccines such as Infanrix Hexa, Hexaci Ma/Hexyon, Twinrix, Ambirix, and Comvax are widely used for the prevention of hepatitis B infection. It is observed that combination vaccines are a major revenue-generating segment. Factors such as higher patient compliance, reduced dose frequency, better disease control, coverage of vaccines under the national immunization program, and reduced chances of missing an immunization are driving the growth of the combination vaccine market globally. It is observed that monovalent vaccines such as RecombiVax HB, Hendrix, and Engerix-B are approved for the treatment of hepatitis B infection.

Based on end-user age group, the global hepatitis B vaccine market is segmented as follows:

  • Vaccines for Adults Against Hepatitis B
  • Pediatric Hepatitis B Vaccines

The Hepatitis B virus causes life-threatening liver disease; the vaccine is more effective than any other treatment in preventing infection. The choice of hepatitis B vaccine varies with age. Adult Hepatitis B Vaccines are used for active immunization of people over the age of 18 and over the age of 21 in Europe and the United States, respectively. Hepatitis B is one of the most common traveler's diseases, which can be avoided by vaccination. Governments across the world have mandated the immunization of travelers, which is acting as a growth driver for the hepatitis B vaccine market across the world. It is observed that in 2016, adult hepatitis B vaccines held the largest market share, as adults have a high risk of developing hepatitis B infections due to end-stage renal disease, drug abuse, and HIV infection, which is driving the market growth of adult hepatitis B vaccines globally.

In terms of immunogenicity, pediatric vaccines differ from adult vaccines. Pediatric hepatitis B vaccines are used for the prevention of hepatitis B infection in infants, toddlers, and adolescents because babies and young children are at higher risk for developing the potentially fatal complications of the infection. It is estimated that pediatric hepatitis B vaccines will show a steady growth rate during the forecast period. Pediatric vaccines such as Infanrix, Hexa, Hexacima/Hexyon, Ambirix, and Comvax have been linked to adverse reactions. In the market, Infanrix Hexa is widely accepted.

For the purpose of this study, the hepatitis B vaccine market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Hepatitis B is a life-threatening liver disease that can cause acute and chronic liver infections and may lead to cirrhosis and liver cancer. Safe and effective vaccines are available on the market to prevent hepatitis B infection. According to the World Health Organization (WHO), the prevalence of hepatitis B is highest in the Western Pacific, and in the African region, more than 6% of the adult population is affected by hepatitis B infection. In Southeast Asia and the European region, it is estimated that 2% and 1.6% of the general population are affected by hepatitis B, respectively.

The burden of hepatitis B infection is considerably lower in the American population, which represents approximately 0.7% of the overall population. It is observed that in the base year 2016, North America was a major revenue-contributing segment. Factors such as the higher cost of vaccines, immunization programs, and favorable R&D activities are driving market growth in North America. Currently, Asia Pacific is not a major revenue-generating segment, but it is estimated that it will show the highest CAGR during the forecast period. Rising healthcare awareness, populous countries, increased awareness of vaccines, and government initiatives in vaccination programs would influence the growth of the hepatitis B vaccine market in the Asia Pacific region.

Frequently Asked Questions:

The market for Hepatitis B Vaccine Market is expected to reach US$ 1.89 Bn By 2025.

The Hepatitis B Vaccine Market is expected to see significant CAGR growth over the coming years, at 3.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Sanofi Pasteur, Serum Institute of India, Sinovac Biotech, Dynavax Technologies are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  May 2017
Category:  Pharmaceuticals
Report ID:   58438
Report Format:   PDF
Pages:   120
Rating:    4.7 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support